The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical impact of an online tool to guide choice of therapy (Tx) for patients (Pts) with advanced renal cell carcinoma (RCC).
Timothy A Quill
No relevant relationships to disclose
Brian I. Rini
Consultant or Advisory Role - AVEO; Bristol-Myers Squibb; GlaxoSmithKline; Pfizer
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Pfizer
Eric Jonasch
Consultant or Advisory Role - AVEO; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Research Funding - GlaxoSmithKline; Novartis; Pfizer
Andrew Bowser
No relevant relationships to disclose
Jim A. Mortimer
No relevant relationships to disclose
Robert John Motzer
Consultant or Advisory Role - Genentech; Pfizer
Research Funding - Astellas Pharma; AVEO; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer